Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06824987 · ClinicalTrials.gov registry record · Phase 2

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

A Phase 2 study of APOL1-mediated Kidney Disease, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
96
Enrollment target
20
Study locations

NCT06824987: Recruiting Phase 2 study of APOL1-mediated Kidney Disease, sponsored by AstraZeneca.

NCT06824987 is a Phase 2 study of APOL1-mediated Kidney Disease that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 96 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06824987, a Phase 2 study of APOL1-mediated Kidney Disease, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
96 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.

Primary Outcome

To assess the effect of AZD2373 versus placebo in reducing albuminuria

Conditions Studied

APOL1-mediated Kidney Disease

Interventions

  • COMBINATION_PRODUCT Placebo
  • COMBINATION_PRODUCT AZD2373-Arm 1
  • COMBINATION_PRODUCT AZD2373-Arm 2
  • DEVICE APOL1 Genotyping Clinical Trial Assay

Study Locations (20)

Georgia

  • Research Site - Atlanta
  • Research Site - Augusta
  • Research Site - Augusta
  • Research Site - Columbus
  • Research Site - Columbus
  • Research Site - Duluth
  • Research Site - Hinesville
  • Research Site - Lawrenceville

Florida

  • Research Site - Brandon
  • Research Site - Miami
  • Research Site - Miami
  • Research Site - Orlando
  • Research Site - Pompano Beach

California

  • Research Site - Beverly Hills
  • Research Site - Gardena
  • Research Site - Los Angeles
  • Research Site - Valencia

Alabama

  • Research Site - Alabaster
  • Research Site - Birmingham
  • Research Site - Irondale

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2025-03-05
Est. Completion 2027-08-30
Phase Phase 2
AstraZeneca

1,285 total trials

What NCT06824987 shows while recruiting

NCT06824987 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower).

The record links to 1 condition, with APOL1-mediated Kidney Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT06824987 names 20 study sites across 4 states, led by Georgia, Florida, California.

Frequently Asked Questions

What is clinical trial NCT06824987 about?

NCT06824987 is a clinical study titled "Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease". The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with...

What is the current status of trial NCT06824987?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2025-03-05. Estimated completion is 2027-08-30.

What conditions does trial NCT06824987 study?

This clinical trial studies the following conditions: APOL1-mediated Kidney Disease.

What interventions are being tested in trial NCT06824987?

The interventions under investigation include: Placebo (COMBINATION_PRODUCT), AZD2373-Arm 1 (COMBINATION_PRODUCT), AZD2373-Arm 2 (COMBINATION_PRODUCT), APOL1 Genotyping Clinical Trial Assay (DEVICE).

Who is sponsoring clinical trial NCT06824987?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06824987 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for APOL1-mediated Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06824987's enrollment target sits among peer trials

96 747th of 2000 higher than 1,243 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03401762 · 96 participants · NA

    Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

  • NCT03471260 · 96 participants · Phase 1

    Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • NCT03549559 · 96 participants · NA

    Imaging Histone Deacetylase in the Heart

  • NCT03841058 · 96 participants · Phase 2

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06824987

Source: ClinicalTrials.gov NCT06824987, the US trial registry maintained by the National Library of Medicine. NCT06824987 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.